Catalysts
PRODUCTS
-
Ergomed places patients and their care partners’ needs at the core of our services. We strive to build empathetic relationships with patients and their care partners, not just during the trial but also before and after. Our team provides personalized support, aiming to alleviate the burden of study participation. Ergomed and our trusted partners are deeply committed to bringing lifesaving treatments to patients.
-
Mycenax’s state-of-the-art biomanufacturing site is PIC/S GMP certified. Our highly qualified and well-trained team routinely manufactures high-quality biopharmaceutical products by mammalian cell culture and microbial fermentation processes. We continuously invest in our technologies and infrastructure to ensure that we constantly meet your evolving needs of today and tomorrow.
-
CPI EDB offers solid state switches designed for operation in UFH-band, L-band, S-band, C-band, X-band, Ku-band, and Ka-band applications. With peak power handling ranging from 10 to 500 W, these switches are also capable of providing low loss with isolation up to 40 dB.
-
KRYTAR's 4-50 GHz directional couplers are crafted for system applications necessitating external leveling, precise monitoring, signal mixing, or swept transmission and reflection measurements.
-
Part of our Evolve range, this RTU-based, automated fill-finish platform can fill liquids and powders on the same line. Ideal for dual chamber formats and reconstitution devices.
WHITE PAPERS AND CASE STUDIES
-
Cutting Costs, Not Corners: How PRI-TECH® Transformed Biosolids Odor Control At Bergen Point WWTP
The Suffolk County Department of Public Works tested the effectiveness and cost-efficiency of PRI-TECH® in controlling odors at a wastewater treatment plant. The technology successfully treated odors and reduced operating costs.
-
Leverage Apps To Reduce Line Changeover Time From 14 Days To 3
A global biopharma leader modernized its complex equipment changeover process using an innovative platform to achieve faster execution, fewer errors, and greater visibility through digitized, validatable SOPs.
-
Resolving Odor Complaints With Targeted Solutions Restore Community Confidence
The South Dearborn Regional Sewer District in Lawrenceburg, Indiana, provides regional wastewater treatment services for three cities and an international distillery. The 6 mgd treatment plant is located in an area of high population growth and is surrounded by many retail operations and other commercial developments. In addition, a heavily traveled state highway runs by the treatment plant.
-
Use Of Epiontis ID In A Phase 2 Psoriasis Trial
Mirikizumab’s Phase 2 trial explores IL-23 inhibition in psoriasis, measuring immune cell changes to assess its potential for long-term disease control and flare-up prevention.
-
Timely Lab Data To Inform Outreach To Healthcare Professionals
Learn how you can leverage a system that offers flexible data delivery formats and seamless integration into commercialization workflows while also ensuring HIPAA-compliant deidentified data for patient privacy.
-
RO Membrane Protection For A Desalination Plant In Mejillones, Chile
Read about a seawater desalination plant that presented with several performance issues and chose the HOD UV system to control biofouling on the RO membranes.
-
Rescuing A Global Program For NDA Success
Explore the collaboration that enabled FDA approval of a novel chronic-condition therapy, rescued a high-risk program, and demonstrated a unified “one-team” approach by reworking the sponsor's SAP.
-
How Vanguard Clinical Harnesses CDMS/EDC For Faster Results
Uncover how this CRO was able to stay agile by choosing a CDMS/EDC partner that prioritized sponsor needs and streamlined operations to achieve top-tier results swiftly.
-
Changing The Clinical Feasibility Game With AI
AI is only as good as the data it’s built upon. Our customized AI platforms are constructed on a foundation of trustworthy, carefully curated data to produce detailed, expert-driven responses.
-
Optimizing Early-Stage Oncology
A strategic partnership enables a U.S. biotech company to address the struggles with their Phase I first-in-human oncology trial.
-
Quick And Easy Pipe Repair In Virginia Saves Thousands Of Dollars
Learn how JCSA efficiently replaced ten dresser-style couplings on a 16" steel pipe spanning a 600-foot bridge using the versatile HYMAX VERSA coupling, enabling a quick and cost-effective repair without removing the pipe.
-
Supporting Participants Through National Travel Disruptions
A sudden travel shutdown threatened a critical clinical visit. Rapid rescheduling, coordinated logistics, and clear communication ensured engagement and the ability to continue without interruption.
NEWS
-
Enhanc3D Genomics Launches Suite Of 3D Multi-Omics Solutions To Accelerate Drug Development1/14/2025
Enhanc3D Genomics (‘Enhanced’ or ‘the Company’), an innovator in 3D genomics technology, today announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug discovery.
-
The Persistence Of PFAS - IDTechEx Covers Growing PFAS Regulations4/24/2025
Per- and polyfluoroalkyl substances (PFAS) are a broad group of chemicals that includes both polymers and non-polymers used in many applications, from transport to consumer products.
-
Be Part of Photonics Future: CIOE 2025 Visitor Registration Live Now!4/9/2025
The 26th China International Optoelectronic Exposition (CIOE 2025) is set to take place from September 10–12, 2025, at the Shenzhen World Exhibition & Convention Center, spanning 240,000 square meters of exhibition space.
-
Drawing Inspiration From Ancient Chemical Reactions3/20/2025
To help find solutions to the planet’s climate crisis, MIT Associate Professor Daniel Suess is looking to Earth’s ancient past.
-
Quantum Biopharma Announces Signing Of An Agreement With A Global Pharmaceutical Contract Research Organization To Prepare An IND (Investigational New Drug) Application Package For Lucid-21-302 (Lucid-MS), A First-In-Class Treatment For Multiple Sclerosis5/20/2025
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that it has signed an agreement with a global pharmaceutical contract research organization to prepare an IND (Investigational New Drug) application package for Lucid-21-302 (Lucid-MS) with the US FDA.
ABOUT
Catalysts
Catalysts work by changing the structure of a molecule or by bonding to reactant molecules causing them to combine, react, and release a product or energy. For example, a catalyst is required in order for oxygen and hydrogen to bond, combine and produce water.
Catalysts increase the rate of chemical reactions. Unlike a reagent that gets consumed as apart of the chemical reaction, catalysts do not get consumed in the reaction. They can actually participate in multiple chemical transformations.Catalysts can be organic, synthetic or metal.
All processes need energy to take place. Processes require a very high level of energy in order to spark or start if a catalyst isn’t present. When a catalyst is present the amount of energy required to spark the reaction is lowered and that makes the reaction happen faster and more efficiently.
Catalytic effects vary depending on other substances present that are a part of the chemical reactions. There are certain substances that can inhibit the effectiveness of a catalyst like poisons, and other substances that promote or increase the effect of the catalyst. Inhibitors or negative catalysts are very important in medicine to treat mental illnesses, high blood pressure, cancer and many other diseases.
Catalysts are often used to help crack, or split, larger organic molecules like hydrocarbons into simpler molecules. It does this by breaking carbon-carbon bonds. The speed of the splitting process depends heavily on what specific catalyst is used and the temperature. Applications of this technology include oil and petrochemical industries.